| Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NCT02975609) | Shanghai Chest Hospital | 2016-11-01 |
| Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome (NCT02890849) | Xinqiao Hospital of Chongqing | 2016-10-01 |
| Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection (NCT03269162) | lihegen | 2016-09-30 |
| Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing (NCT03609918) | Tianjin Medical University Cancer Institute and Hospital | 2016-09-27 |
| Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation (NCT03265496) | Centre Oscar Lambret | 2016-07-07 |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma (NCT04276025) | Klinikum Bayreuth GmbH | 2016-07-01 |
| Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy (NCT02284308) | Maastricht Radiation Oncology | 2016-07-01 |
| Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation (NCT02795884) | Yonsei University | 2016-06-01 |
| Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients (NCT02766348) | Shenzhen Hornetcorn Bio-technology Company, LTD | 2016-05-01 |
| Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations (NCT02759614) | Guangdong Association of Clinical Trials | 2016-04-01 |
| Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects (NCT03030430) | Bio-Thera Solutions | 2016-03-15 |
| Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies (NCT02648724) | Symphogen A/S | 2016-03-01 |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors (NCT02573259) | Pfizer | 2016-02-10 |
| Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease (NCT02469701) | howard safran | 2016-02-01 |
| Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (NCT02607813) | Novartis Pharmaceuticals | 2016-01-18 |
| S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC (NCT02631460) | Sun Yat-sen University | 2015-12-01 |
| Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients (NCT02526537) | Lunxu Liu | 2015-11-11 |
| Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NCT02326285) | AIO-Studien-gGmbH | 2015-11-01 |
| A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors (NCT02563548) | Halozyme Therapeutics | 2015-10-22 |
| Afatinib in NSCLC With HER2 Mutation (NCT02369484) | ETOP IBCSG Partners Foundation | 2015-09-16 |
| Study of Endostar Subcutaneous Injection in NSCLC (NCT02652234) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2015-08-01 |
| A Rollover Protocol of Dacomitinib For Patients In Japan (NCT02382796) | Pfizer | 2015-07-10 |
| Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia (NCT02515032) | Smartfish AS | 2015-07-01 |
| Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients (NCT02454842) | Rain Oncology Inc | 2015-06-01 |
| Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC) (NCT02145637) | Yonsei University | 2015-05-07 |
| Study of the CD40 Agonistic Monoclonal Antibody APX005M (NCT02482168) | Apexigen America, Inc. | 2015-05-01 |
| High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (NCT02404675) | Betta Pharmaceuticals Co., Ltd. | 2015-04-01 |
| Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) (NCT02121899) | Myriad Genetic Laboratories, Inc. | 2015-04-01 |
| Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases (NCT02385136) | Zhejiang Cancer Hospital | 2015-04-01 |
| A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC (NCT02387216) | Elevation Oncology | 2015-02-01 |
| Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC) (NCT02283021) | Hadassah Medical Organization | 2015-01-01 |
| Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine® (NCT02354274) | Olfred Hansen | 2015-01-01 |
| Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients (NCT01859650) | Sheffield Teaching Hospitals NHS Foundation Trust | 2014-12-11 |
| Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer (NCT01799161) | Eckhard Podack | 2014-12-01 |
| LUMINIST: LUng Cancer Molecular Insights Non Interventional Study (NCT02300831) | AstraZeneca | 2014-12-01 |
| Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients (NCT02226757) | Amsterdam UMC, location VUmc | 2014-08-01 |
| A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care (NCT02279004) | Dana-Farber Cancer Institute | 2014-07-03 |
| Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer (NCT02272127) | Nanfang Hospital, Southern Medical University | 2014-07-01 |
| Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up (NCT02121925) | Myriad Genetic Laboratories, Inc. | 2014-05-01 |
| EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer (NCT02183870) | University of Cologne | 2014-05-01 |
| A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations (NCT02109016) | Clovis Oncology, Inc. | 2014-04-01 |
| Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor (NCT02069158) | Cristiana Sessa | 2014-04-01 |
| Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy (NCT01963195) | Anhui Medical University | 2014-02-01 |
| Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients. (NCT02029222) | Maastricht Radiation Oncology | 2013-12-01 |
| Circulating Fibrocytes in Non-small Cell Lung Cancer. (NCT01998425) | Chang Gung Memorial Hospital | 2013-11-01 |
| A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (NCT02000947) | MedImmune LLC | 2013-10-25 |
| ATOM_local Ablative Therapy (NCT01941654) | Chinese University of Hong Kong | 2013-09-18 |
| Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC (NCT02140333) | The First Affiliated Hospital of Guangzhou Medical University | 2013-08-01 |
| Combination of Metformin With Gefitinib to Treat NSCLC (NCT01864681) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2013-05-01 |
| Afatinib Plus Nimotuzumb for NSCLC (NCT01861223) | Samsung Medical Center | 2013-05-01 |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (NCT01829971) | Mirna Therapeutics, Inc. | 2013-04-01 |
| PET Response During Chemoradiation of Lung Cancer (NCT02315053) | The Netherlands Cancer Institute | 2013-03-21 |
| A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status (NCT01100827) | National University Hospital, Singapore | 2013-02-01 |
| An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib (NCT01932229) | Sheba Medical Center | 2013-02-01 |
| Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients (NCT01719536) | Betta Pharmaceuticals Co., Ltd. | 2012-12-01 |
| Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC (NCT01742767) | Universität Duisburg-Essen | 2012-11-01 |
| De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (NCT01697163) | Severance Hospital | 2012-10-01 |
| Cabazitaxel in Relapsed and Metastatic NSCLC (NCT01852578) | Hellenic Oncology Research Group | 2012-09-01 |
| A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy (NCT01560195) | Jiangsu HengRui Medicine Co., Ltd. | 2012-04-01 |
| Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC (NCT01562210) | The Netherlands Cancer Institute | 2012-04-01 |
| Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer (NCT04522687) | Shanghai Cancer Hospital, China | 2012-01-01 |
| Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene (NCT01221077) | Astellas Pharma Inc | 2011-04-08 |
| Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy (NCT01579630) | Taipei Veterans General Hospital, Taiwan | 2011-03-01 |
| Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC (NCT02175381) | Hellenic Oncology Research Group | 2011-02-01 |
| Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer (NCT01553656) | Exelixis | 2011-02-01 |
| Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients (NCT01290809) | Maastricht Radiation Oncology | 2011-01-01 |
| Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer (NCT01222572) | Dana-Farber Cancer Institute | 2010-12-01 |
| Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer (NCT01172925) | Hamilton Health Sciences Corporation | 2010-11-01 |
| IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients. (NCT01219348) | Inge Marie Svane | 2010-06-01 |
| Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC (NCT01024829) | The Netherlands Cancer Institute | 2010-05-01 |
| Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC) (NCT01368848) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2010-04-01 |
| Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC (NCT02179567) | Hellenic Oncology Research Group | 2010-03-01 |
| A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) (NCT01100931) | National Cancer Institute (NCI) | 2010-02-01 |
| Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC (NCT01769066) | Fudan University | 2009-12-01 |
| Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors (NCT01105182) | The First Affiliated Hospital of Guangzhou Medical University | 2009-11-01 |
| Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer (NCT00874848) | HiberCell, Inc. | 2009-08-01 |
| A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction (NCT03448146) | PTS International Inc. | 2009-08-01 |
| A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer (NCT00924209) | National Cancer Institute (NCI) | 2009-03-01 |
| Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN (NCT00831909) | AstraZeneca | 2009-01-01 |
| Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation (NCT00522639) | Maastricht Radiation Oncology | 2008-10-01 |
| Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients (NCT00754364) | Armando Santoro, MD | 2008-10-01 |
| Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy (NCT00777179) | Genzyme, a Sanofi Company | 2008-10-01 |
| Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia (NCT00866970) | CSL Behring | 2008-09-01 |
| Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy (NCT00702975) | Radboud University Medical Center | 2008-09-01 |
| NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer (NCT00749346) | NovoCure Ltd. | 2008-05-01 |
| A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation (NCT00655161) | GlobeImmune | 2008-04-01 |
| Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment (NCT00752076) | National Taiwan University Hospital | 2008-04-01 |
| Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III (NCT00620269) | National Cancer Center, Korea | 2008-02-01 |
| Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival (NCT01261598) | Centre Henri Becquerel | 2007-11-01 |
| CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL (NCT00576225) | CTI BioPharma | 2007-09-01 |
| A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer (NCT00297089) | AbbVie (prior sponsor, Abbott) | 2006-11-01 |
| Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) (NCT00298415) | Intergroupe Francophone de Cancerologie Thoracique | 2006-03-01 |
| A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (NCT00269828) | CTI BioPharma | 2005-12-01 |
| A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens (NCT00294736) | OSI Pharmaceuticals | 2005-11-01 |
| Iressa as Second Line Therapy in Advanced NSCLC-Asia (NCT00478049) | AstraZeneca | 2005-09-01 |
| A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer (NCT00283634) | Millennium Pharmaceuticals, Inc. | 2005-08-01 |
| Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) (NCT00153803) | Dartmouth-Hitchcock Medical Center | 2005-05-01 |
| Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer (NCT00683514) | Pierre Fabre Medicament | 2005-04-01 |
| Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III (NCT00172380) | National Taiwan University Hospital | 2005-02-01 |
| Iressa v BSC (Best Supportive Care) in First Line NSCLC (NCT00259064) | AstraZeneca | 2004-09-01 |